Opana Sales Calls Didn't Cause Rx Rise, Economist Testifies
An economist testifying for Endo in a California opioid trial said Tuesday that a data set of 250,000 sales calls related to the opioid Opana ER showed no overall effect on...To view the full article, register now.
Already a subscriber? Click here to view full article